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• Consider carrying out tests in primary care if a woman reports unexplained weight loss, fatigue, or changes in bowel habit.
• Carry out appropriate tests for ovarian cancer in any woman aged 50 years or over who has had symptoms within the past 12 months that suggest irritable bowel syndrome, 6 because IBS rarely presents for the first time in women of this age.
• Advise any woman who is not suspected of having ovarian cancer to return to her general practitioner if her symptoms become more frequent or persistent.
First tests
• Measure serum CA125 concentration in primary care in women with symptoms that suggest ovarian cancer.
• If serum CA125 concentration is 35 IU/mL or greater, arrange an ultrasound scan of the abdomen and pelvis.
• If the ultrasound suggests ovarian cancer, refer the woman urgently for further investigation. 5 • For any woman who has normal serum CA125 concentration (less than 35 IU/mL), or CA125 of 35 IU/mL or greater but a normal ultrasound: -Assess her carefully for other clinical causes of her symptoms and investigate if appropriate -If no other clinical cause is apparent, advise her to return to her general practitioner if her symptoms become more frequent and/or persistent.
Establishing the diagnosis in secondary care
Tumour markers • Measure the serum CA125 concentration in secondary care in all women with suspected ovarian cancer, if this has not already been done in primary care.
• In women aged under 40 years with suspected ovarian cancer, measure serum concentrations of α fetoprotein, β human chorionic gonadotrophin, and CA125, to identify women who may not have epithelial ovarian cancer.
Malignancy indices
Calculate a score on the risk of malignancy index I (RMI I) (box 1) after ultrasonography, and refer all women with a score of 250 or greater to a specialist multidisciplinary team.
GUIDELINES
Recognition and initial management of ovarian cancer: summary of NICE guidance Ovarian cancer is the leading cause of death from gynaecological cancer in the United Kingdom, and its incidence is rising. It is the fifth most common cancer in women, with a lifetime risk of about 2% in England and Wales.
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The outcome for women with ovarian cancer is generally poor, with an overall five year survival rate of less than 35%. 2 Most women have had symptoms for months before presentation, and as these are frequently non-specific, delays often occur between presentation and referral to a specialist. 3 Greater awareness of the disease and appropriate initial investigations in primary and secondary care are needed to enable earlier referral and optimum treatment. This article summarises the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the recognition and initial management of women with ovarian cancer. 
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and infracolic omentectomy; biopsies of any peritoneal deposits; random biopsies of the pelvic and abdominal peritoneum and assessment of the retroperitoneal lymph nodes. 8 Do not include systematic retroperitoneal lymphadenectomy (block dissection of lymph nodes from the pelvic side walls to the level of the renal veins) as part of standard surgical treatment in women with suspected ovarian cancer whose disease seems to be confined to the ovaries (that is, seems to be stage I disease). 
Adjuvant systemic chemotherapy for stage I disease

Management of advanced (stage II to IV) ovarian cancer Primary surgery
When performing surgery in women with ovarian c ancer, whether before chemotherapy or after neoadjuvant chemotherapy, the objective should be complete r esection of all macroscopic disease.
Intraperitoneal chemotherapy
Do not offer intraperitoneal chemotherapy to women with ovarian cancer, except as part of a clinical trial.
Support needs of women with newly diagnosed ovarian cancer
• Offer all women with newly diagnosed ovarian cancer information about their disease (including psychosocial and psychosexual matters) that: -Is available at the time they want it -Includes the amount of detail that they want and are able to deal with -Is in a suitable format, including written information.
• Ensure that available information covers:
-The stage of the disease, treatment options, and prognosis -How to manage the side effects of both the disease and its treatments to maximise wellbeing -Sexuality and sexual activity -Fertility and hormone treatment -Symptoms and signs of disease recurrence -Genetics, including the chances of family members developing ovarian cancer -Self help strategies to optimise independence and coping -Where to go for support, including support groups -How to deal with emotions such as sadness, depression, anxiety, and a feeling of a lack of control over the outcome of the disease and treatment. 
Management of suspected early (stage I) ovarian cancer
Role of systematic retroperitoneal lymphadenectomy Conduct an assessment of the retroperitoneal lymph nodes as part of optimal surgical staging in women with suspected ovarian cancer whose disease seems to be confined to the ovaries (that is, seems to be stage I disease). Optimal surgical staging consists of midline laparotomy to allow thorough assessment of the abdomen and pelvis; a total abdominal hysterectomy, bilateral salpingo-oophorectomy,
Box 1 | Risk of malignancy index I 7
The risk of malignancy index I (RMI I) combines three presurgical features: serum CA125 concentration, menopausal status, and ultrasound score. The RMI is a product of the score for the ultrasound scan (U), the score for menopausal status (M), and the serum CA125 concentration (IU/mL), thus: RMI I = U x M x CA125 Scoring system • The ultrasound result is scored 1 point for each of the following characteristics: multilocular cysts, solid areas, metastases, ascites, and bilateral lesions (U=0 for an ultrasound score of 0), U=1 for an ultrasound score of 1, U=3 for an ultrasound score of 2-5.
• The menopausal status is scored as follows: 1 = premenopausal and 3 = postmenopausal. The classification of post-menopausal is for women who have had no period for more than one year or women over the age of 50 who have had a hysterectomy.
• Serum CA125 concentration can vary from 0 to hundreds or even thousands of units. 
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A 22 year old man presents with a resolving episode of mild jaundice after an influenza-like illness. He reports a previous episode after an appendicectomy, which also resolved spontaneously, but he is worried about the implications of this recurrence. Biochemical records from his surgical admission show a slightly raised bilirubin concentration of 48 µmol/L (normal < 22 µmol/L), but alanine aminotransferase, alkaline phosphatase, γ-glutamyl transferase and albumin were all within normal limits.
What you should cover
The history and biochemistry in this patient strongly suggest Gilbert's syndrome, a hereditary (usually autosomal recessive) condition caused by impaired hepatic bilirubin clearance. 1 Gilbert's syndrome is present in 5-10% of Western European populations with 1 in 3 of those affected unaware that they have it. 2 3 Diagnosis of the disorder is often made after an incidental finding of
Overcoming barriers
Primary care doctors have understandably been concerned that they should not needlessly subject women with nonspecific symptoms to the distress and unpleasantness of investigations to detect this relatively rare disease. However, their caution is likely to have contributed to delays in diagnosing ovarian cancer, with women often presenting as emergencies or to inappropriate management pathways. The recommendations and supporting evidence should give healthcare professionals the confidence to start the appropriate investigations, better direct referrals to the correct pathway, and raise awareness among women. The recommended tests and necessary clinical resources will need to be made available and accessible.
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Provenance and peer review: Commissioned; not externally peer reviewed. isolated hyperbilirubinaemia on routine liver biochemistry testing. Bilirubin is the normal by-product of the breakdown of red blood cells (haemoglobin). Patients with Gilbert's syndrome have a defect in the gene that encodes for glucuronyltransferase, which results in a 60-70% reduction in the liver's ability to conjugate bilirubin. This subsequent increase in serum concentrations of unconjugated bilirubin can lead to intermittent episodes of non-pruritic jaundice, which can be precipitated by fasting, infections, dehydration, surgery, physical exertion, and lack of sleep. Symptoms, including tiredness, that occur during episodes of jaundice are caused by the precipitating factor and do not result directly from Gilbert's syndrome.
Drugs that inhibit glucuronyltransferase activity such as gemfibrozil, and the protease inhibitors atazanavir and indinavir, can also trigger episodes of jaundice. 4 Altered metabolism of paracetamol has been shown in a subgroup This is part of a series of occasional articles on common problems in primary care. The BMJ welcomes contributions from GPs.
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• Provocation tests, such as looking for a rise in unconjugated bilirubin after a 48 hour fast are impractical and non-specific for Gilbert's syndrome. 8 • In cases where diagnostic doubt remains or patients are particularly anxious, genetic testing can be done for confirmation, but this should rarely be necessary.
• Liver or biliary imaging and referral to secondary care are not needed.
• Rarer causes of unconjugated hyperbilirubinaemia (see box) can be excluded with a comprehensive history and the simple investigations listed.
• Over-investigation is the greatest danger to patients with this benign condition.
Patient advice and education
• Explain to him that the disorder has occurred as a result of a genetic variation in the way he metabolises the pigment bilirubin, which results in him having slightly higher circulating levels than the average person.
• Reassure him that he does not have a disease and that episodes of jaundice are not contagious and will resolve spontaneously within a few days.
• Jaundice does not indicate or result in liver damage, and the condition does not reduce life expectancy or affect life insurance.
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• Dietary restrictions are not necessary and alcohol is safe within recommended limits.
• Recommend that he informs medical staff of his disorder if admitted to hospital and when prescribed new medication.
• Tell him to consult you if he has an episode of jaundice that is more severe or persistent than usual because this may indicate a separate condition.
